Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Restated) (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Restated) (Unaudited) - USD ($)
$ in Thousands
Total
Restated
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series C Preferred Stock
Common Stock
Common Stock
Restated
Additional Paid-in Capital
Additional Paid-in Capital
Restated
AOCI Attributable to Parent
AOCI Attributable to Parent
Restated
Accumulated Deficit
Accumulated Deficit
Restated
Beginning balance at Dec. 31, 2020 $ (48,736)   $ 52,809 $ 35,228 $ 65,222 $ 2   $ 10,131   $ (982)   $ (211,146)  
Beginning balance, shares at Dec. 31, 2020 [1]     21,615,723 8,306,818 12,804,176 17,664,015              
Exercise of stock options 295             295          
Exercise of stock options, shares [1]           251,500              
Stock compensation expense 2,507             2,507          
Net loss (19,698)                     (19,698)  
Foreign currency translation adjustments 32                 32      
Ending balance at Mar. 31, 2021 (65,600)   $ 52,809 $ 35,228 $ 65,222 $ 2   12,933   (950)   (230,844)  
Ending balance, shares at Mar. 31, 2021 [1]     21,615,723 8,306,818 12,804,176 17,915,515              
Beginning balance at Dec. 31, 2021 190,207 $ 190,207         $ 15   $ 438,696   $ 732   $ (249,236)
Beginning balance, shares at Dec. 31, 2021             151,154,614            
Exercise of stock options $ 638             638          
Exercise of stock options, shares 492,064         492,064              
Vesting of restricted stock units, shares           4,014              
Stock compensation expense $ 2,289             2,289          
Net loss (11,792) $ (11,792)                     $ (11,792)
Foreign currency translation adjustments 1,859                 1,859      
Ending balance at Mar. 31, 2022 $ 183,201         $ 15   $ 441,623   $ 2,591   $ (261,028)  
Ending balance, shares at Mar. 31, 2022           151,650,692              
[1] The shares of the Company’s common and convertible preferred stock, prior to the Merger (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 1.7058 established in the Merger.